One of the TNF Superfamily Members: Bifunctional Protein, TNFR2-Fc-IL-1ra

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1155)

Abstract

Many anti-inflammatory agents have been exploited for the treatment of inflammatory diseases by targeting the most potent proinflammatory cytokines including tumor necrosis factor (TNF) and interleukin-1 (IL-1). Theoretically, simultaneous neutralization or blocking two important inflammatory mediators might achieve a synergistic therapeutic effect. A recombinant fusion protein, TNFR2-Fc-IL-1ra (TFI), was developed as bifunctional inflammatory inhibitor. TFI was able to strongly neutralize TNF activity and to antagonize IL-1 receptor in the cell binding inhibition assays, suggesting that TFI could be used as a bifunctional ligand with enhanced anti-inflammatory effect.

Key words

Proinflammatory cytokines Bifunctional protein Synergistic therapeutic effect Bioreactor Affinity Expression and purification 

Notes

Acknowledgements

This work was supported by 863 grant 2012AA02A406 and State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences.

References

  1. 1.
    Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE (2007) Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol 147:227–235PubMedCentralPubMedGoogle Scholar
  2. 2.
    Strober W, Fuss IJ (2011) Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140:1756–1767.e1PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Miller AM, Mcinnes IB (2011) Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation. Curr Pharm Des 17:1–8PubMedCrossRefGoogle Scholar
  4. 4.
    Vinay DS, Kwon BS (2011) The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin Exp Immunol 164:145–157PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Perrier S, Darakhshan F, Hajduch E (2006) IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett 580:6289–6294PubMedCrossRefGoogle Scholar
  6. 6.
    Bresnihan B (2001) The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. BioDrugs 15:87–97PubMedCrossRefGoogle Scholar
  7. 7.
    Xie B, Liu S, Wu S, Chang A, Jin W, Guo Z et al (2013) A novel bifunctional protein TNFR2-Fc-IL-1ra (TFI): expression, purification and its neutralization activity of inflammatory factors. Mol Biotechnol 54:141–147PubMedCrossRefGoogle Scholar
  8. 8.
    Jia Q, Wu HT, Zhou X, Gao J, Zhao W, Aziz J et al (2010) A “GC-rich” method for mammalian gene expression: a dominant role of non-coding DNA GC content in regulation of mammalian gene expression. Sci China Life Sci 53:94–100PubMedCrossRefGoogle Scholar
  9. 9.
    Eibl R, Kaiser S, Lombriser R, Eibl D (2010) Disposable bioreactors: the current state-of-the-art and recommended applications in biotechnology. Appl Microbiol Biotechnol 86:41–49PubMedCrossRefGoogle Scholar
  10. 10.
    Baarsch MJ, Wannemuehler MJ, Molitor TM, Murtaugh MP (1991) Detection of tumor necrosis factor α from porcine alveolar macrophages using an L929 fibroblast bioassay. J Immunol Methods 140:15–22PubMedCrossRefGoogle Scholar
  11. 11.
    Steinkasserer A, Solari R, Mott HR, Aplin RT, Robinson CC, Willis AC et al (1992) Human interleukin-1 receptor antagonist, high yield expression in E. coli and examination of cysteine residues. FEBS Lett 310:63–65PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.State Key Laboratory of Biochemical EngineeringInstitute of Process Engineering, Chinese Academy of SciencesBeijingChina
  2. 2.National Key Laboratory of Biochemical EngineeringInstitute of Process Engineering, Chinese Academy of SciencesBeijingChina

Personalised recommendations